Core Viewpoint - CICC maintains the profit forecast for Giant Bio (02367) for 2025-2026, with the current stock price corresponding to a P/E of 16x for 2025 and 13x for 2026. The target price is set at HKD 70, reflecting a potential upside of 68% based on the approval of medical beauty products and the recovery of the cosmetics business [1]. Company Status - On October 23, Giant Bio announced the approval of its "Recombinant Type I α1 Collagen Lyophilized Fiber" as a Class III medical device, marking it as China's first recombinant Type I natural sequence collagen facial injection product. This approval is expected to enhance the company's long-term growth potential in the medical beauty sector [2][3]. Product Approval and Market Potential - The approved recombinant collagen product is indicated for facial tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet. The medical beauty injection market is still considered a blue ocean, and the company is expected to benefit from first-mover advantages, with projected revenues potentially reaching CNY 1 billion in the long term [3]. Commercialization Readiness - The company has made substantial preparations for commercialization, including team building and initial communications with doctors and institutions. As of the first half of 2025, the company has established a presence in approximately 1,700 public hospitals and 3,000 private hospitals and medical beauty clinics, leveraging its existing sales experience to enhance product visibility and market promotion [4]. Future Pipeline and Growth Opportunities - The company has a rich pipeline of future products, including non-crosslinked hydrating products currently under registration, crosslinked neck wrinkle products with priority review status, and crosslinked nasolabial fold products progressing smoothly. The approval of the first medical beauty product validates the company's technological leadership and safety, with further product launches expected to broaden its growth trajectory. Additionally, the cosmetics business is anticipated to improve gradually with the recovery of promotional activities [5].

Macro Strategy - The "Innovation Bull" market is entering a consolidation phase, driven by a positive cycle of capital pricing and industrial implementation under policy guidance [1][13] - Current macro policies are still being implemented, and the "KOT" valuation system is gradually improving, with medium to long-term funds expected to enter the market annually [1][13] - Market liquidity and valuations have improved, with public fund net values exceeding 1, indicating potential for accelerated fund issuance [1][13] - The market is likely to extend towards technology sectors such as computing power, chips, robotics, and energy storage as the "Innovation Bull" evolves into a comprehensive bull market [1][13] Fixed Income - The report discusses how to identify arbitrage opportunities in the Sci-Tech Bond ETF component bonds, focusing on bonds with an implied rating of AA+ or higher and smaller issuance sizes [2][14] - The report emphasizes the importance of liquidity and credit quality in selecting bonds for inclusion in the ETF, with a preference for bonds issued by central state-owned enterprises [2][14] - The report highlights the potential for price appreciation of bonds that are included in the ETF due to passive fund inflows [2][15] Industry Analysis - The report identifies the "brain" as a key component in the development of embodied intelligence, with various companies exploring different technological paths [4][16] - The embodied intelligence market is expected to grow rapidly, with significant investment in brain technology, which is seen as the most critical and challenging aspect of the market [4][16] - Key players in the market include companies like 品茗科技, 银河通用, and Tesla, among others, with a recommendation to focus on these related stocks [4][16] Company Recommendations - 派能科技 (688063) is projected to recover from impairment and exchange rate impacts, with expected net profits of 1.0/5.0/7.2 billion yuan for 2025-2027, reflecting significant growth [5][17] - 巨子生物 (02367.HK) has received approval for its first type I recombinant collagen product, which is expected to drive growth in the medical beauty sector, with projected net profits of 25.66/32.14/40.46 billion yuan for 2025-2027 [6][18] - 联合动力 (301656) reported a slight decline in net profit but maintains a positive long-term outlook, with expected net profits of 11.3/16.8/25.8 billion yuan for 2025-2027 [7][21] - 杰瑞股份 (002353) continues to show growth potential with projected net profits of 30/35/40 billion yuan for 2025-2027, despite short-term delivery challenges [8][22]

Core Insights - The top three stocks with net inflows from southbound funds are Yingfu Fund (02800) with 1.995 billion, China National Offshore Oil Corporation (00883) with 1.424 billion, and SMIC (00981) with 636 million [1][2] - The top three stocks with net outflows are Hua Hong Semiconductor (01347) with -299 million, GigaDevice Semiconductor (02367) with -179 million, and Zhaojin Mining (01818) with -162 million [1][2] - In terms of net inflow ratios, GX Hengsheng Technology (02837) leads with 89.26%, followed by Far East Horizon (03360) at 80.25%, and Tuhu-W (09690) at 67.29% [1][2] - The stocks with the highest net outflow ratios include Huadian International Power (01071) at -74.23%, CIMC Enric (03899) at -63.04%, and Weilu Group (01196) at -57.66% [1][2] Net Inflow Rankings - Yingfu Fund (02800) recorded a net inflow of 1.995 billion, representing a 15.63% increase, with a closing price of 26.420 [2] - China National Offshore Oil Corporation (00883) saw a net inflow of 1.424 billion, with a net inflow ratio of 46.50% and a closing price of 19.500 [2] - SMIC (00981) had a net inflow of 636 million, with a net inflow ratio of 10.38% and a closing price of 74.850 [2] Net Outflow Rankings - Hua Hong Semiconductor (01347) experienced a net outflow of -299 million, with a net outflow ratio of -9.94% and a closing price of 75.950 [2] - GigaDevice Semiconductor (02367) had a net outflow of -179 million, with a net outflow ratio of -31.12% and a closing price of 38.620 [2] - Zhaojin Mining (01818) recorded a net outflow of -162 million, with a net outflow ratio of -19.70% and a closing price of 29.840 [2] Net Inflow Ratio Rankings - GX Hengsheng Technology (02837) achieved a net inflow ratio of 89.26%, with a net inflow of 36.552 million and a closing price of 7.310 [3] - Far East Horizon (03360) had a net inflow ratio of 80.25%, with a net inflow of 27.178 million and a closing price of 7.140 [3] - Tuhu-W (09690) recorded a net inflow ratio of 67.29%, with a net inflow of 19.987 million and a closing price of 18.050 [3] Net Outflow Ratio Rankings - Huadian International Power (01071) had the highest net outflow ratio at -74.23%, with a net outflow of -23.262 million and a closing price of 4.400 [3] - CIMC Enric (03899) recorded a net outflow ratio of -63.04%, with a net outflow of -15.158 million and a closing price of 7.880 [3] - Weilu Group (01196) experienced a net outflow ratio of -57.66%, with a net outflow of -10.037 million and a closing price of 12.090 [3]

Core Insights - The company, Juzhi Biotechnology, has received approval for its recombinant type I α1 collagen protein lyophilized fiber, which is indicated for facial dermal tissue filling to correct dynamic wrinkles such as glabellar lines, forehead lines, and crow's feet [1][2]. Product Development - Juzhi Biotechnology has four recombinant collagen injection products under application, including liquid and solid formulations for facial wrinkles and gels for nasolabial folds and neck wrinkles [1]. - The company’s recombinant collagen gel for neck wrinkles has entered the priority approval channel, which is expected to expedite the approval process for its products [2]. Innovation and Patents - The company has received patent authorization for two innovative products: a recombinant type IV collagen composition for sensitive skin care and a fermented ginseng product aimed at cognitive impairment and memory improvement [2]. Financial Projections - Juzhi Biotechnology is a leader in the recombinant collagen sector in China, with projected net profits of 2.566 billion, 3.214 billion, and 4.046 billion yuan for 2025-2027, reflecting year-on-year growth rates of 24%, 25%, and 26% respectively [3]. - The latest closing price corresponds to a price-to-earnings ratio of 16, 12, and 10 for 2025-2027, maintaining a "buy" rating [3].

Core Viewpoint - The approval of the recombinant type I α1 collagen freeze-dried fiber product by Juzi Bio marks a significant milestone as it is the first recombinant type I natural sequence collagen facial injection product in China, with potential for over 1 billion in sales in the long term [1] Group 1: Product Approval and Market Potential - Juzi Bio's recombinant type I collagen product is primarily aimed at facial dermal tissue filling to correct dynamic wrinkles, including forehead and crow's feet [1] - The product's long-term sales potential is estimated to exceed 1 billion, with a notable profit margin, referencing Jinbo Biotech's net profit margin of 45.66% in 1H25 [1] - The current market for injectable recombinant collagen is limited, with Jinbo Biotech focusing on recombinant type III humanized collagen products, which have shown significant revenue growth [1] Group 2: Brand Performance and Sales Growth - The Q3 performance of the 可复美 (Kefumei) brand shows a recovery in online sales, with GMV reaching 615 million and a year-on-year increase of 20% [2] - The brand's promotional activities, including collaborations with influencers, have contributed to restoring brand visibility and sales [2] - The company has expanded its international presence, with Kefumei products entering 13 Watsons stores in Singapore [2] Group 3: Financial Forecast and Valuation - The company maintains its net profit forecasts for 2025-2027 at 26.00 billion, 32.03 billion, and 38.12 billion, respectively, with corresponding EPS of 2.53, 3.11, and 3.71 [2] - The target price is set at 85.0 HKD, based on a 31x PE for 2025, reflecting the company's leading position in the medical aesthetics sector and resilient sales performance [2]

Core Viewpoint - The approval of the first injectable recombinant collagen product by the company marks a significant milestone in its product matrix, which now includes aesthetic injection products, post-surgery repair dressings, and functional skincare [1] Group 1: Product Approval and Market Potential - The newly approved recombinant type I α1 collagen lyophilized fiber is intended for facial dermal tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet [1] - The Chinese aesthetic injection market is projected to reach CNY 147 billion by 2027, with the injectable collagen segment expected to grow to CNY 16.8 billion, indicating high growth potential [2] - Currently, there are four approved facial injectable recombinant collagen products in China, including the company's product and others from Jinbo Biotech [2] Group 2: Competitive Landscape and Channel Advantages - The company's product competes with Jinbo Biotech's offerings, which also target the dermal layer for wrinkle filling, suggesting future competition in eye and facial anti-aging scenarios [2] - The company has a strong channel advantage through its established brand recognition and deep distribution network in the aesthetic market, which is expected to enhance the market potential of the new injectable products [2] Group 3: Future Product Pipeline - The company has two additional injectable collagen products in the approval stage, with expected approval timelines in December 2024 and August 2025, which will further enrich its aesthetic product matrix [3] - These upcoming products will cover a range of anti-aging scenarios from dynamic wrinkle improvement to overall skin texture enhancement [3] Group 4: Financial Outlook and Ratings - The company maintains a "Buy" rating with a target price of HKD 58.35, despite a projected decline in online sales for its brand, which may affect overall revenue growth [4] - The company's revenue growth forecast for 2025 has been adjusted down to 12%, with a long-term CAGR for its brand's revenue growth revised from 26% to 14.5% [4]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its self-developed "Recombinant Type I α1 Collagen Freeze-Dried Fiber," marking a significant advancement in the medical aesthetics sector and enhancing its competitive position in the market [1]. Industry Summary - The market for recombinant collagen in China is projected to reach 54.7 billion yuan by 2025, with the medical aesthetics segment expected to grow to 7 billion yuan, driven by high biocompatibility and low allergenic risk [2]. - The company is positioned as the second domestic entity to receive approval for recombinant collagen, allowing it to benefit from industry expansion [2]. Company Summary - The company's recombinant collagen product is designed to improve skin structure and reduce dynamic wrinkles, showcasing its technological advantages and creating a barrier to entry for competitors [1]. - Despite short-term sales fluctuations in skincare products due to reduced collaborations, the company maintains strong brand recognition and product efficacy, with expectations for recovery through optimized channel structures and scientific marketing [2]. - The company plans to expand the application of recombinant collagen beyond skincare and medical aesthetics to include hair growth and whitening, while also exploring international market opportunities [2]. - Revenue forecasts for 2025-2027 have been adjusted to 6.917 billion, 8.540 billion, and 10.419 billion yuan respectively, with net profits projected at 2.452 billion, 2.989 billion, and 3.603 billion yuan [2].

Core Insights - The recombinant collagen injection material market is seeing new entrants, with Juzi Bio (2367.HK) receiving approval for its recombinant type I collagen product for facial dermal filling, potentially disrupting the dominance of Jinbo Bio (920982.BJ) [1][2] Company Developments - Juzi Bio's product is composed of recombinant type I collagen, specifically a sequence of 753 amino acids, which does not have a triple helix structure, and is aimed at correcting dynamic facial wrinkles [1][2] - Jinbo Bio previously held a monopoly in the recombinant collagen injection market, with projected revenues of 1.443 billion yuan for 2024, reflecting over 80% year-on-year growth [2] Market Dynamics - The materials used by Juzi Bio and Jinbo Bio differ, with Juzi's focusing on type I collagen for structural support, while Jinbo's core material is type III collagen, which is responsible for elasticity [3] - Both companies have received approval for similar indications related to facial dermal filling, indicating that competition in the market is likely to intensify as more products gain regulatory approval [3]

Investment Rating - The report maintains a "Buy" rating for the company [2][16]. Core Insights - The approval of the first recombinant type I natural sequence collagen facial injection product in China marks a significant milestone for the company, enhancing its competitive position in the medical aesthetics market [7]. - The new product is expected to drive revenue growth and reshape the competitive landscape in the collagen product category, showcasing the company's technological and industrial capabilities [7]. - The company has demonstrated strong revenue growth across its product lines, with notable performance from its flagship products and new launches [7]. Financial Data and Profit Forecast - Projected revenue growth from 2023 to 2027 shows a significant increase, with revenues expected to rise from 3,524 million RMB in 2023 to 10,691 million RMB in 2027, reflecting a compound annual growth rate (CAGR) of approximately 49% [6][8]. - The net profit attributable to the parent company is forecasted to grow from 1,452 million RMB in 2023 to 3,726 million RMB in 2027, with a CAGR of around 23% [6][8]. - The company's gross margin is expected to remain stable, averaging around 82% over the forecast period [6]. Product Performance and Market Position - The flagship product, "可复美," generated revenue of 25.4 billion RMB in the first half of 2025, representing a year-on-year growth of 22.7% [7]. - The company has successfully launched new products that have gained market recognition, contributing to overall revenue growth [7]. - Direct sales channels have shown strong growth, with direct sales revenue reaching 23.3 billion RMB in the first half of 2025, up 26.5% year-on-year [7].

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company has successfully obtained approval for its self-developed "Recombinant Type I α1 Collagen Freeze-Dried Fiber," marking it as the first of its kind in China, with various specifications suitable for facial dermal tissue filling [2] - The recombinant collagen market in China is projected to reach 54.7 billion yuan by 2025, with the medical aesthetics market expected to grow to 7 billion yuan, indicating significant growth potential for the company [3] - The company is positioned as the second domestic enterprise to receive approval for recombinant collagen, allowing it to benefit from industry expansion [3] - The skincare segment is currently facing short-term sales fluctuations but is expected to stabilize and recover through optimized channel structures and strong brand recognition [4] Summary by Sections Medical Aesthetics - The company's recombinant collagen product showcases technical advantages and strengthens its leading position in the market, with a focus on improving skin structure and reducing dynamic wrinkles [3] - The product's unique formulation and research barriers enhance its market competitiveness [3] Skincare Products - Short-term sales have been impacted by a reduction in collaboration with influencers, but the brand's strength and product recognition remain robust [4] - The company aims to recover sales through channel optimization and continued consumer confidence driven by scientific marketing [4] Financial Projections - Revenue forecasts for 2025-2027 are adjusted to 6.917 billion, 8.540 billion, and 10.419 billion yuan respectively, with net profits projected at 2.452 billion, 2.988 billion, and 3.603 billion yuan [5] - The earnings per share (EPS) for the same period are expected to be 2.29, 2.79, and 3.36 yuan, with corresponding price-to-earnings (PE) ratios of 17, 14, and 11 times [5][8]